Frequently Asked Questions

As a Public Benefit Corporation, AlphaRose is legally committed to balancing the interests of shareholders with the broader public benefit of developing treatments for underserved patient populations. Our mission is to create a sustainable model for rare disease drug development that prioritizes patient access while maintaining financial viability.

Traditional pharmaceutical development economics don't work for ultra-rare diseases affecting fewer than 500 patients. AlphaRose has developed a platform that dramatically reduces the time and cost of drug development, making it economically viable to treat individual rare diseases that would otherwise be ignored by traditional pharma.

AlphaRose was founded by Casey McPherson, whose daughter Rose was diagnosed with HNRNPH2, an ultra-rare neurogenetic disease. After successfully developing a preclinical treatment for Rose's condition in under a year, Casey founded AlphaRose to scale this approach and help millions of other children with rare genetic diseases.

abcDNA is AlphaRose's proprietary backbone chemistry acquired from Alpha Anomeric SA (France). It eliminates sulfur linkages while preserving the phosphate structure required for gene silencing. This results in reduced immune activation, fewer off-target effects, and a cleaner safety profile than conventional phosphorothioate chemistry.

AlphaRose employs two AI platforms: Argus, which analyzes public and proprietary gene datasets to identify viable antisense targets, and MetaMorph, which computationally predicts and optimizes ASO sequences for efficacy and safety. These tools replace months of wet-lab screening with hours of computational design.

Rosiphersen is AlphaRose's lead therapeutic candidate, designed to treat HNRNPH2 (Bain Syndrome). It silences the toxic gain-of-function mutation while demonstrating simultaneous HNRNPH1 upregulation in human neurons. Preclinical toxicology studies showed no observable adverse effects, and IND-enabling studies are planned.

The Monarch platform is AlphaRose's integrated drug discovery and development system that combines Argus (target identification), MetaMorph (sequence optimization), abcDNA (proprietary chemistry), and SOT Caller (epigenetic modulation) to accelerate the path from genetic diagnosis to treatment.

Traditional drug development takes 10+ years and costs over $2 billion with only a 5% success rate. AlphaRose's platform compresses timelines to months instead of years, reduces costs to under $30 million for clinical trials, and focuses on diseases where the science is well-understood but the business model has been lacking.

AlphaRose's competitive advantages include proprietary abcDNA chemistry with improved safety profiles, AI-powered drug design tools, a vertically integrated CRO (RareLabs), deep expertise in rare disease regulatory pathways, and a Public Benefit Corporation structure that aligns all stakeholders around patient outcomes.

AlphaRose is headquartered in Austin, Texas, with research facilities in Boston, Massachusetts and GMP manufacturing in Houston, Texas.

AlphaRose Therapeutics, Inc. was incorporated in 2023 as a Delaware Public Benefit Corporation.

RareLabs is targeting $1.4 million in revenue for 2026 through preclinical service contracts. The lead program Rosiphersen is projected at $300-600K per patient per year upon commercialization, with peak annual product revenue of $100-700M.

AlphaRose has acquired abcDNA proprietary chemistry from Alpha Anomeric SA (France), integrated RareLabs as its preclinical CRO, and developed proprietary AI platforms (Argus and MetaMorph) for drug design and target identification.

Yes, AlphaRose is actively exploring partnerships with international pharmaceutical companies and research institutions to expand the reach of its platform globally.

Rare disease therapies benefit from orphan drug designation (7 years U.S. market exclusivity, 10 years EU), priority review vouchers worth $75-100M, tax credits for clinical research, reduced FDA fees, and expedited regulatory pathways.

There are over 200 million children worldwide living with rare genetic diseases, with 95% having no approved treatment. AlphaRose's platform has already screened over 300 monogenic CNS diseases and identified multiple candidates amenable to ASO therapy.

You can reach AlphaRose Therapeutics at contact@alpharosetherapeutics.com. Our offices are located in Austin, TX (headquarters), Houston, TX (GMP manufacturing), and Boston, MA (research). Visit our website or contact us directly to learn more about partnership opportunities, investment, or collaboration.